Literature DB >> 11783457

Effects of common ophthalmic preservatives on ocular health.

R Noecker.   

Abstract

Preservatives are an important component of ophthalmic preparations, providing antimicrobial activity in the bottle and preventing decomposition of active drug. Often underrecognized, however, are the significant cytotoxic effects of preservatives associated with long-term therapy and especially use of multiple preserved drugs. The most common preservatives in ophthalmic preparations for glaucoma and surface eye disease-benzalkonium chloride (BAK), chlorobutanol, sodium perborate, and stabilized oxychloro complex (SOC)-were reviewed. Compared with other preservatives, SOC caused the least amount of damage to rabbit corneal epithelial cells. BAK has demonstrated cytotoxic effects in cell culture, as well as in animal and human studies. Physicians should consider treatment with new-generation preparations containing low-risk preservatives such as SOC, especially in patients receiving multiple ophthalmic medications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11783457     DOI: 10.1007/bf02853166

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  62 in total

1.  Comparative clinical study of conjunctival toxicities of newer generation fluoroquinolones without the influence of preservatives.

Authors:  Han Sang Park; Jun Hun Lee; Hong Kyun Kim
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

Review 2.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

3.  An optimised protocol for the production of autologous serum eyedrops.

Authors:  L Liu; D Hartwig; S Harloff; P Herminghaus; T Wedel; G Geerling
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

4.  Drug-induced cicatrising granulomatous conjunctivitis.

Authors:  Alon Kahana; Marcus M Marcet; Daniel M Albert; Andrew T Thliveris
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

5.  [Pharmacokinetics of the anterior eye].

Authors:  K Bell; N Pfeiffer; F H Grus
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

6.  Potential toxicity of topical ocular solutions.

Authors:  Nevio Cimolai
Journal:  CMAJ       Date:  2019-08-12       Impact factor: 8.262

7.  Comparison of contamination rates between preserved and preservative-free fluoroquinolone eyedrops.

Authors:  Mo Sae Kim; Hong Kyun Kim; Joon Mo Kim; Chul Young Choi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-12       Impact factor: 3.117

8.  Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension.

Authors:  Anna Galanopoulos; Ivan Goldberg
Journal:  Clin Ophthalmol       Date:  2009-06-02

9.  Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany.

Authors:  Thomas Kaercher; Patricia Buchholz; Friedemann Kimmich
Journal:  Clin Ophthalmol       Date:  2009-06-02

10.  Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients.

Authors:  Michael B Horsley; Malik Y Kahook
Journal:  Clin Ophthalmol       Date:  2009-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.